Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2026-01.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101 Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Endocrinol Metab > Volume 40(3); 2025 > Article
Original Article
Hypothalamus and pituitary gland Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study
Keypoint
-Panhypopituitary patients were found to have higher risks of cardiovascular disease, stroke, and mortality.
-Male patients were more prone to ischemic and hemorrhagic stroke, while female patients had a higher risk of coronary artery disease and a greater overall mortality risk.
Seung Shin Park1,2,3*orcid, Hyunmook Jeong4*orcid, Chang Ho Ahn5, Min Jeong Park1,2, Yong Hwy Kim3, Kwangsoo Kim4orcid, Jung Hee Kim1,2,3orcid
Endocrinology and Metabolism 2025;40(3):469-483.
DOI: https://doi.org/10.3803/EnM.2024.2176
Published online: February 11, 2025

1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

2Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

3Pituitary Center, Seoul National University Hospital, Seoul, Korea

4Department of Transdisciplinary Medicine, Institute of Convergence Medicine with Innovative Technology, Seoul National University Hospital, Seoul, Korea

5Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

6Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Corresponding authors: Kwangsoo Kim. Department of Transdisciplinary Medicine, Institute of Convergence Medicine with Innovative Technology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-4489, Fax: +82-2-6072-5304, E-mail: kksoo716@gmail.com
Jung Hee Kim. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-4839, Fax: +82-2-764-2199, E-mail: jhee1@snu.ac.kr
These authors contributed equally to this work.
• Received: September 12, 2024   • Revised: November 26, 2024   • Accepted: December 16, 2024

Copyright © 2025 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 4,499 Views
  • 108 Download
prev next
Full Article

Download PDF Download PDF

  • Background
    Panhypopituitarism is a condition of combined deficiency of multiple pituitary hormones, which requires lifelong hormone replacement therapy. Hormone deficiency or inadequate hormone replacement may contribute to cardiovascular disease. Here, we aimed to investigate the burden of cardiovascular, cerebrovascular diseases and mortality in patients with panhypopituitarism.
  • Methods
    A total of 5,714 patients with panhypopituitarism were enrolled in the Korean National Health Insurance Service database from 2003 to 2020. Panhypopituitarism was defined according to the International Classification of Diseases, 10th Revision (ICD- 10) codes for hypopituitarism, pituitary adenoma, or craniopharyngioma and the continuous prescription of thyroid hormone and glucocorticoids. The risks of all-cause mortality, coronary artery disease (CAD), heart failure (HF), ischemic stroke, and intracranial hemorrhage were compared between patients with panhypopituitarism and age-, sex-, and index year-matched controls.
  • Results
    The mean age of patients with panhypopituitarism and matched controls was 55.1 years, and men accounted for 51.5%. Patients with panhypopituitarism showed significantly higher all-cause mortality compared to matched controls after adjustment for covariates (hazard ratio [HR], 2.18; 95% confidence interval [CI], 1.95 to 2.43 in men and HR, 3.09; 95% CI, 2.78 to 3.44 in women). Additionally, there were higher risks of CAD, HF, ischemic stroke, and intracranial hemorrhage in both sexes, except for CAD in men.
  • Conclusion
    Patients with panhypopituitarism have elevated risks of cardiovascular and cerebrovascular diseases as well as increased mortality. These risks are particularly prominent for all-cause mortality in women. Therefore, proactive monitoring for cardiovascular and cerebrovascular complications is required in patients with panhypopituitarism.
  • Keywords: Pituitary diseases; Cardiovascular diseases; Mortality; Stroke
Hypopituitarism is characterized by a partial or complete hormone deficiency in the anterior or posterior pituitary gland. The prevalence of hypopituitarism is not well established; however, it is approximately 290 to 455 cases per million individuals, with an incidence of approximately 42.1 cases per million [1]. Gonadotropin deficiency is the most common (87% of cases), followed by growth hormone (GH) deficiency (61%), adrenocorticotropic hormone deficiency (62%), and thyroid-stimulating hormone deficiency (64%) [1]. Panhypopituitarism, specifically, is indicated in the case of all pituitary hormone deficiencies. Panhypopituitarism has various etiologies including pituitary tumors such as pituitary adenomas and craniopharyngiomas, which account for approximately 60%–76% of cases. Peripituitary tumors, surgery, radiation, head trauma, autoimmune diseases, and genetic mutations can lead to a broad spectrum of hormonal deficiencies [2,3].
Among the complications of panhypopituitarism, the increased risk of cardiovascular diseases and an elevated mortality rate are of the greatest concern. Patients with hypopituitarism have a 1.2–4.5 times higher risk of all-cause mortality than the general population [3-5]. Cardiovascular and cerebrovascular diseases are leading risk factors for increased mortality rates in these patients [4-6]. However, the effects of panhypopituitarism on cardiovascular outcomes and mortality have not been comprehensively evaluated in large population-based studies.
Hypopituitarism predisposes individuals to cardiovascular diseases through several mechanisms. GH deficiency leads to an increase in fat content and a decrease in muscle mass, adversely affecting the lipid profile and leading to an increased risk of cardiovascular and cerebrovascular diseases [7,8]. Estrogen deficiency is associated with increased metabolic risks, such as alterations in lipid profiles, and is known to affect endothelial function [9,10]. Low testosterone levels are associated with reduced muscle mass, increased fat mass, and increased insulin resistance [11]. Thyroid hormone levels are directly related to cardiac contractility, and hypothyroidism is associated with changes in lipid profiles such as hypercholesterolemia [12].
The sex-specific impact on cardiovascular outcomes in these patients remains to be elucidated. The impact of sex hormones on cardiovascular health in hypopituitary patients is not fully understood. Estrogen and testosterone can affect cardiovascular risk factors differently, but their specific roles in these patients need further investigation. The interaction between sex and other cardiovascular risk factors such as diabetes mellitus, hypertension, ad dyslipidemia in hypopituitary patients is not wellcharacterized [13]. Generally, women have a higher average life expectancy and relatively lower cardiovascular risk compared to men. However, several studies showed that the increased risk was higher in female patients compared to male patients with hypopituitarism [3-5,14-16].
To address these gaps, we conducted a nationwide, population-based study using data from the Korean National Health Insurance Service (NHIS). Our aims were to (1) delineate the specific cardiovascular outcomes and all-cause mortality attributable to panhypopituitarism; (2) elucidate the sex-specific differences in these risks; and (3) identify the risk factors for cardiovascular outcomes and all-cause mortality in patients with panhypopituitarism. By leveraging a large representative cohort with a long follow-up period and robust statistical methods, we aimed to provide a more comprehensive and contemporary understanding of the cardiovascular and mortality risks associated with panhypopituitarism. These findings may guide the development of tailored risk-management strategies for this patient population.
Study design and population
This nationwide, population-based, retrospective cohort study used data from the Korean NHIS. The NHIS is a mandatory health insurance system that covers approximately 97% of the South Korean population and provides comprehensive information on demographic characteristics, disease diagnoses, procedures, surgery, and drug prescription records [17].
Adult patients aged ≥19 years diagnosed with panhypopituitarism were included. For each patient with panhypopituitarism, 10 age-, sex-, and index year-matched controls (n=57,140) were randomly selected from among individuals without International Classification of Diseases, 10th Revision (ICD-10) codes for pituitary disease from 2002 to 2020. A flow diagram of the study participants is shown in Fig. 1. Using the NHIS database, we screened 216,065 individuals diagnosed with pituitary disease between 2003 and 2020. First, we screened patients with pituitary diseases having at least two registrations of ICD-10 codes and special V-codes for rare and intractable disease, irrespective of the type, for panhypopituitarism (E23, E23.0–E23.7), pituitary tumors (D352, D443, C751), craniopharyngiomas (D353, D444, C752), postoperative panhypopituitarism (E893), benign neoplasm of the pituitary gland (D35.2, V162), and Sheehan syndrome (E23.0, V165). Patients diagnosed with hyperpituitarism, acromegaly (ICD-10 code E22), and Cushing disease (ICD-10 code E240) were excluded. Finally, we enrolled 5,714 patients who met the following criteria: (1) patients who received thyroid hormone and glucocorticoid medications for ≥ 180 days within 1 year from the last prescription date and patients who were prescribed glucocorticoid medications for ≥ 335 days annually; (2) patients who received prescriptions for thyroid hormone or glucocorticoids after or within 30 days before the ICD-10 diagnosis of panhypopituitarism; and (3) patients for whom the initial prescription of glucocorticoids and thyroid hormone was within a 180-day interval.
We established a comparison group using a matching methodology. For each identified case of panhypopituitarism, we selected 1:10 age-, sex-, and index year-matched controls from the general population who had undergone appendectomy (Q2861–2863) without any pituitary diseases, yielding a total of 57,140 control subjects. Ethical approval for this study was granted by the Institutional Review Board of Seoul National University Hospital (IRB No. E-2406-062-1543), which waived the requirement for informed consent given the retrospective nature of the study and the use of anonymized data.
Definition of study outcomes
The outcomes of this study were newly diagnosed cardiovascular disease, cerebrovascular disease, and all-cause mortality. Coronary artery disease was defined by the presence of the ICD-10 codes I20–I25 at least once during hospitalization and a record of coronary artery angiography (procedure codes HA607, E0721, E0723, O1640, O1641, O1642, O1647, O1648, O1649, OA640, OA641, OA642, OA647, OA648, OA649, M6551, M6552, M6553, M6554, M6561, M6562, M6563, M6564, M6565, M6566, M6567, M6571, and M6572). Heart failure was defined by the presence of the ICD-10 codes I50, I42, and I43 more than twice in an outpatient setting or at least once during hospitalization. Ischemic stroke and intracranial hemorrhage were defined by the presence of ICD-10 codes (I63–I66 for ischemic stroke and I60–I62 for intracranial hemorrhage) at least once during hospitalization and records of least one brain imaging study or procedure (codes HE101, HE102, HE135, HE136, HE201, HE202, HE235, HE236, HE301, HE302, HE501, HE502, HE535, and HE536). Composite cardiovascular outcome was defined as a combination of coronary artery disease, ischemic stroke, intracranial hemorrhage, and heart failure.
The index date was established as the earliest date on which either thyroid hormone or glucocorticoid hormone treatment was initiated. After a 1-year washout period, we collected outcome data from the index date until December 31, 2020, or the date of death. The follow-up duration was defined as the index date to the date of onset of cardiovascular outcomes, date of death, or December 31, 2020, whichever came first.
Data collection
Baseline demographic and clinical characteristics including age, sex, income level, and comorbidities were analyzed. Hypertension was defined by the presence of the ICD-10 code I10 more than twice in outpatient settings or at least once during hospitalization and prescriptions of antihypertensive drugs for >180 days. Dyslipidemia was defined by the presence of the ICD-10 codes E78 more than twice in an outpatient setting or at least once during hospitalization. Diabetes mellitus was defined by the presence of ICD-10 codes E11–E14 more than twice in outpatient settings or at least once during hospitalization and a prescription of antidiabetic agents or insulin for >180 days.
Brain surgery was defined by at least one record of a surgical procedure code for a craniotomy or transsphenoidal approach (S4631–4639, S4743). Radiation therapy was defined by a record of a procedure code for brain radiotherapy (HD051–059). Similarly, radiosurgery was defined by at least one record of a procedure code for stereotactic radiosurgery of the brain (HD113–114).
Individuals were classified as users of GH, sex hormones (estrogen for females and testosterone for males), and desmopressin if they had a minimum of two prescriptions for these medications recorded within 365.25 days from the index date.
Statistical analyses
The baseline characteristics were compared between the panhypopituitarism and control groups. Continuous variables were presented as mean±standard deviation, whereas categorical variables were presented as number (%). For comparing the continuous and categorical variables, Student t-test and chi-square test was used, respectively.
The incidence rates of cardiovascular disease and all-cause mortality were calculated by dividing the number of events by the total person-years of follow-up. The risks of mortality and new onset cardiovascular outcomes were analyzed using the Cox proportional hazards model. Hazard ratios (HRs) and 95% confidence intervals (CIs) were presented for heart failure, coronary artery disease, ischemic stroke, and intracranial hemorrhage. Initially, adjustments were made for age and index year through inverse probability of treatment weighting (IPTW) (Model 1). Subsequently, additional adjustments were made to model 1 to include baseline hypertension, dyslipidemia, diabetes mellitus, and income (model 2) to enhance the comprehensiveness of the risk analysis. Univariate and multivariate analyses were conducted using the Cox proportional hazards model to determine the impact of various risk factors on cardiovascular outcomes and all-cause mortality in patients with panhypopituitarism. The cumulative incidence of coronary artery disease, heart failure, ischemic stroke, intracranial hemorrhage, composite outcome of cardiovascular disease, and mortality were analyzed using the Kaplan–Meier survival analysis and the log-rank test.
Subgroup analyses were performed to investigate potential effect modifiers, including sex and age (≥40 or <40 years). Sensitivity analyses were performed to assess the robustness of the findings.
All statistical analyses were conducted using R version 4.1 (Foundation for Statistical Computing, Vienna, Austria). Statistical significance was set at P<0.05.
Baseline characteristics
The baseline characteristics of the patients with panhypopituitarism and their age-, sex-, and index year-matched controls are presented in Table 1. A total of 5,714 patients with panhypopituitarism (2,945 men and 2,769 women) were matched with 57,140 controls. The mean age was 55.1±15.1 years, and men accounted for 51.5% in both groups. The panhypopituitarism group showed a higher prevalence of several comorbidities including hypertension (36.5% vs. 31.3%), dyslipidemia (56.4% vs. 41.2%), and diabetes mellitus (17.7% vs. 10.7%) (all P<0.001). Regarding treatment modalities, approximately half (47.7%) of the patients with panhypopituitarism underwent brain surgeries such as transsphenoidal surgery and craniotomy. A smaller proportion of patients underwent radiation therapy (3.2%) or radiosurgery (9.9%). Among patients with panhypopituitarism, 1.9% used GHs; 8.2%, sex hormones; and 31.7%, desmopressin.
Cardiovascular outcomes and all-cause mortality
The HRs for cardiovascular diseases and mortality in patients with panhypopituitarism compared with matched controls are presented in Tables 2, 3. During the median follow-up period of 93.6 months for patients with panhypopituitarism and 105.0 months for controls, the composite cardiovascular outcome was observed in 691 patients with hypopituitarism and 4,590 controls. Among men, the HR for the composite cardiovascular outcome was 1.87 (95% CI, 1.66 to 2.12; P<0.001), after adjusting for age, index year, baseline hypertension, dyslipidemia, diabetes mellitus, and income. Men with panhypopituitarism had increased risks of individual cardiovascular events, including heart failure (HR, 1.30; 95% CI, 1.09 to 1.54; P=0.004), ischemic stroke (HR, 3.36; 95% CI, 2.86 to 3.96; P<0.001), and intracranial hemorrhage (HR, 3.28; 95% CI, 2.10 to 5.11; P<0.001), with the exception of coronary artery diseases (Table 2, Fig. 2).
Similarly, female patients with panhypopituitarism faced a higher risk of the composite cardiovascular outcome (HR, 1.58; 95% CI, 1.41 to 1.78; P<0.001) and individual events such as coronary artery disease (HR, 1.79; 95% CI, 1.23 to 2.61; P=0.002), heart failure (HR, 1.46; 95% CI, 1.26 to 1.70; P<0.001), ischemic stroke (HR, 1.51; 95% CI, 1.25 to 1.81; P<0.001), and intracranial hemorrhage (HR, 2.33; 95% CI, 1.45 to 3.73; P=0.001) (Table 3, Fig. 3).
During the follow-up period, mortality was reported in 865 patients with panhypopituitarism and 4,018 controls. The risk of all-cause mortality was higher in both male (HR, 2.18; 95% CI, 1.95 to 2.43) and female (HR, 3.09; 95% CI, 2.78 to 3.44) patients with panhypopituitarism compared to that in the matched controls (Tables 2, 3).
In a sensitivity analysis conducted in patients aged ≥40 years (Supplemental Tables S1, S2), the findings were consistent with those of the main analysis, demonstrating a significantly increased risk of the composite cardiovascular outcome and all-cause mortality in patients with panhypopituitarism compared with that in controls.
Risk factors of composite cardiovascular outcome and all-cause mortality
We further investigated factors contributing to composite cardiovascular outcomes and all-cause mortality in patients with panhypopituitarism. In men, age (adjusted HR, 1.03; 95% CI, 1.02 to 1.04), diabetes mellitus (adjusted HR, 1.48; 95% CI, 1.12 to 1.95), and hypertension (adjusted HR, 1.42; 95% CI, 1.11 to 1.81) were found to significantly increase the risk of cardiovascular disease (Table 4). Similarly, in women, age (adjusted HR, 1.04; 95% CI, 1.03 to 1.05), diabetes mellitus (adjusted HR, 1.35; 95% CI, 1.02 to 1.77), and hypertension (adjusted HR, 1.59; 95% CI, 1.25 to 2.01) were significant risk factors for cardiovascular disease, whereas GH therapy (adjusted HR, 0.29; 95% CI, 0.09 to 0.92) reduced this risk (Table 5).
In men, significant risk factors for all-cause mortality included age (adjusted HR, 1.06; 95% CI, 1.05 to 1.07) and radiation therapy (adjusted HR, 3.77; 95% CI, 2.32 to 6.12), whereas pituitary surgery was associated with a significantly reduced risk (adjusted HR, 0.70; 95% CI, 0.57 to 0.85) (Table 6). Conversely, in women, age (adjusted HR, 1.06; 95% CI, 1.05 to 1.07), radiation therapy (adjusted HR, 3.54; 95% CI, 2.18 to 5.75), and desmopressin use (adjusted HR, 1.52; 95% CI, 1.23 to 1.89) were significant factors for all-cause mortality (Table 7).
The present nationwide cohort study demonstrated that Korean patients with panhypopituitarism had increased risks of cardiovascular outcomes and mortality compared to age-, sex-, and index year-matched controls. During a median follow-up duration of 7.8 years, both male and female patients with panhypopituitarism had elevated risks of coronary artery disease, heart failure, ischemic stroke, and intracranial hemorrhage compared to their matched controls, except for coronary artery disease in men. In addition, the risk of all-cause mortality was higher in patients with panhypopituitarism than in matched controls, and it was more noticeable in women than in men.
In the present study, both male and female patients with panhypopituitarism exhibited increased risks of heart failure, ischemic stroke, and intracranial hemorrhage compared with controls. Classic risk factors for cardiovascular and cerebrovascular diseases, such as hypertension, diabetes mellitus, and dyslipidemia, were significantly more prevalent in patients with panhypopituitarism. However, this finding persisted after adjusting for major cardiovascular risk factors such as hypertension, diabetes mellitus, and dyslipidemia. Inadequate hormone replacement and newly developed risk factors may contribute to the elevated risk of cardiovascular outcomes. Moreover, this risk may be attributable to body composition changes such as lower lean mass, higher fat mass, endothelial dysfunction, and elevated inflammatory markers in patients with panhypopituitarism, which were not assessed in our study [18-20].
Notably, panhypopituitarism was associated with a strikingly elevated risk of ischemic and hemorrhagic stroke in both men and women. The HRs for ischemic stroke were 3.37 and 1.52 in men and women, whereas those for intracranial hemorrhage were 3.31 and 2.20, respectively. These results align with those of previous studies suggesting that panhypopituitarism may predispose individuals to cerebrovascular events, likely through the aforementioned mechanisms [14,21,22]. Furthermore, intracranial radiation is a well-known risk factor for cerebrovascular diseases [6,14,23]. Intriguingly, the increased risk of stroke was more pronounced in men than in women. Further, the proportion of men who underwent intracranial irradiation was 3.9% (114/2,945), which was approximately 1.5 times higher than the 2.6% (71/2,769) in women (Supplemental Table S3). At baseline, the prevalence of stroke was significantly higher in men than in women, even though the age of men was lower than that of women, and both groups had a similar prevalence of hypertension, dyslipidemia, and diabetes mellitus (Supplemental Table S3). Therefore, there may be other unmeasured risk factors such as smoking, alcohol consumption, body composition, or genetic predisposition.
Intriguingly, the risk of coronary artery disease was higher in female patients with pan-hypopituitarism than in male patients. This pattern of elevated cardiovascular risk among women aligns with previously reported trends [6,13,24]. The lack of protective effect of estrogen against cardiovascular disease in female patients with panhypopituitarism may have significantly contributed to the observed sex discrepancies. Women in the menopausal state demonstrated a higher risk of coronary artery disease than those in the premenopausal state [25], and this risk was mitigated by sex hormone replacement therapy [26]. In this study, sex hormone supplementation was identified as a significant factor for improving composite cardiovascular outcomes in women in the univariate analysis. However, its effect was attenuated in the multivariate analysis, and it did not demonstrate statistically significant results. Further research is needed to evaluate the impact of sex hormone replacement on mortality and composite cardiovascular outcomes in female patients with panhypopituitarism.
On the other hand, the effect of testosterone on cardiovascular outcomes in men remains controversial. Lincoff et al. [27] reported that the effect of testosterone replacement therapy on cardiovascular safety is not inferior to that of a placebo. Paradoxically, this suggests that gonadotropin deficiency in men may have a neutral effect on coronary artery disease, contrary to its effects in women. In addition, a higher risk of ischemic and hemorrhagic stroke in men with panhypopituitarism may be a competing risk factor that prevents them from developing or being diagnosed with coronary artery disease due to increased mortality from stroke events.
Patients with hypopituitarism had an approximately 2-fold higher risk for all-cause mortality than the general population [4-6,14,28,29]. The mortality risks were higher in both men and women with panhypopituitarism than those in their matched controls. Notably, the increased mortality risk was more prominent in women than in men. A meta-analysis reported a standard mortality ratio of 1.33 (95% CI, 0.95 to 1.86) for men and 2.09 (95% CI, 1.51 to 2.89) for women with hypopituitarism [30]. Similarly, female patients with hypopituitarism had a more pronounced mortality risk than male patients [3-6,14,15,31]. This finding may be related to the fact that, in the general population, women have a relatively lower mortality rate than men. Furthermore, the lack of sex hormones in female patients with panhypopituitarism may offset the benefit of a longer life expectancy that women have over men. In the present study, estrogen replacement possibly reduced the risk of cardiovascular complications in the univariate analysis, supporting the aforementioned hypothesis. This outcome has also been consistently observed in other studies, further corroborating these findings [4,32-34]. Moreover, other studies have reported underdiagnosis and undertreatment of hypopituitarism in women as a possible explanation [3,35,36].
Transcranial surgery [4], radiation therapy [4,37], hypogonadism [14], GH deficiency [6,15], craniopharyngioma [4], and arginine vasopressin (AVP) deficiency [37] are associated with increased mortality in patients with hypopituitarism. Certain types of brain surgery, such as the transcranial approach, increase the risk of mortality compared to the transsphenoidal approach [4,30]. However, studies specifically examining the overall risk associated with brain surgery are limited. Brain surgery is associated with reduced mortality in male patients with panhypopituitarism. Patients who undergo brain surgery may have better prognostic profiles than those with unresectable or metastatic pituitary gland tumors. Similar to other studies, we also observed that radiation therapy was a risk factor for increased all-cause mortality. Conversely, sex hormone replacement tended to lower the risk of the composite cardiovascular outcome, although the effect was not statistically significant. This supports the hypothesis that a reduction in female sex hormones contributes to an increase in cardiovascular disease and mortality in patients with panhypopituitarism, thereby creating differences between the sexes. Whether GH supplementation in patients with GH deficiency improves cardiovascular outcomes and mortality remains controversial [28,38-41]. Notably, GH supplementation reduced the risk of adverse cardiovascular outcomes in female patients with panhypopituitarism. While GH supplementation did not show significant effects on cardiovascular outcomes in men, the relatively lower proportion of GH supplementation in men (1.6%) compared to women (2.3%) may have limited our ability to evaluate the impact of GH supplementation on cardiovascular outcomes in the male population. The use of desmopressin, the primary treatment for AVP deficiency, was associated with an increased risk of all-cause mortality in female patients with panhypopituitarism. This finding is consistent with previous studies reporting heightened mortality rates in patients with AVP deficiency [30]. However, the effect of desmopressin on all-cause mortality was not significant in male patients. Notably, desmopressin use was significantly higher in men (37.4%) than that in females (25.6%). Desmopressin use in conditions other than AVP deficiency, such as benign prostatic hyperplasia in men, may mitigate the detrimental effects of AVP deficiency on all-cause mortality.
This study has several strengths. First, we used a large sample of 5,714 patients with panhypopituitarism from the Korean National Cohort NHIS database to analyze the effects of panhypopituitarism on cardiovascular complications and all-cause mortality. Second, age-, sex-, and index year-matched controls were established, allowing for a fully adjusted analysis of the available confounding factors using IPTW. Third, to exclusively identify complications attributable to panhypopituitarism, patients with functional pituitary tumors were excluded. Additionally, for a more accurate assessment of comorbidities, procedure and medication codes were also included along with the ICD-10 diagnostic codes. Fourth, this study compared the effects of pan-hypopituitarism on cardiovascular outcomes in a sex-specific manner. Finally, the robustness of our findings was enhanced by the relatively long median follow-up period of 7.8 years.
This study has several limitations. First, despite adjusting for the major cardiovascular risk factors, the possibility of residual confounding factors could not be excluded. Unmeasured or imperfectly measured confounders, such as lifestyle factors (e.g., diet and physical activity) and body composition, may have influenced the observed associations. Second, the definition of hypopituitarism was based on the operational definitions of prescribed hormone medications, as the NHIS database does not include the results of hormone tests. Accordingly, we restricted patients with hypopituitarism to those who were using glucocorticoids and levothyroxine simultaneously, which corresponded to patients with panhypopituitarism. Third, because of the reliance on claims data to assess medication utilization, accurately capturing the prescriptions of medications not covered by national insurance, such as testosterone or oral contraceptives, is challenging. This difficulty is compounded by the lack of analysis of medication dosages. Consequently, the effects of sex hormone replacement therapy on cardiovascular outcomes and mortality have not been fully evaluated. Fourth, the exact causes of death could not be determined. Therefore, it was challenging to confirm whether an increase in cardiovascular risk directly contributed to an increase in mortality. Finally, the generalizability of the findings to other populations or healthcare systems may be limited, considering the potential differences in genetic backgrounds, environmental factors, and healthcare delivery models.
In conclusion, this nationwide population-based study provides compelling evidence that panhypopituitarism is associated with an increased risk of cardiovascular and cerebrovascular diseases as well as all-cause death. A notable sex-specific trend was observed in patients with panhypopituitarism. Male patients were more prone to ischemic and hemorrhagic stroke, whereas female patients had a higher likelihood of coronary artery disease and a greater overall mortality risk. To mitigate the high morbidity and mortality observed in patients with panhypopituitarism, it is crucial to effectively manage cardiovascular risk factors and optimally replace deficient hormones. Future research should further elucidate the underlying mechanisms contributing to the observed sex disparities, paving the way for personalized precision medicine approaches to optimize outcomes in patients with panhypopituitarism.

Supplemental Table S1.

The Hazard Ratio for Cardiovascular Disease and Mortality in Male Patients ≥40 Years with Panhypopituitarism Compared to Controls (n=2,395)
enm-2024-2176-Supplemental-Table-S1.pdf

Supplemental Table S2.

The Hazard Ratio for Cardiovascular Disease and Mortality in Female Patients ≥40 Years with Panhypopituitarism Compared to Controls (n=2,383)
enm-2024-2176-Supplemental-Table-S2.pdf

Supplemental Table S3.

Comparison of Baseline Characteristics between Male and Female Patients with Panhypopituitarism
enm-2024-2176-Supplemental-Table-S3.pdf

CONFLICTS OF INTEREST

Jung Hee Kim is a deputy editor of the journal. But she was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

AUTHOR CONTRIBUTIONS

Conception or design: C.H.A., K.K., J.H.K. Acquisition, analysis, or interpretation of data: S.S.P., H.J., C.H.A., M.J.P., Y.H.K., K.K., J.H.K. Drafting the work or revising: S.S.P., M.J.P., Y. H.K., K.K., J.H.K. Final approval of the manuscript: K.K., J. H.K.

Acknowledgements
This study was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare of the Republic of Korea (Project No. HI22C0049).
This research was conducted using a customized database provided by the Korean National Health Insurance Service (KNHIS). We express our gratitude to KNHIS for the access to the data, which enabled this study.
Fig. 1.
Flow diagram of study subjects. E23- and E22- denote E23 and E22 and their subordinate codes, respectively.
enm-2024-2176f1.jpg
Fig. 2.
Cumulative incidence curves for (A) coronary artery disease, (B) heart failure, (C) ischemic stroke, (D) intracranial hemorrhage, (E) composite cardiovascular outcome, and (F) all-cause mortality in male patients with panhypopituitarism. Cumulative incidence curves represent the proportion of individuals in each group (patients with panhypopituitarism and matched controls) experiencing coronary artery disease, heart failure, ischemic stroke, intracranial hemorrhage, composite cardiovascular outcomes, and all-cause mortality.
enm-2024-2176f2.jpg
Fig. 3.
Cumulative incidence curves for (A) coronary artery disease, (B) heart failure, (C) ischemic stroke, (D) intracranial hemorrhage, (E) composite cardiovascular outcome, and (F) all-cause mortality in female patients with panhypopituitarism. Cumulative incidence curves represent the proportion of individuals in each group (patients with panhypopituitarism and matched controls) experiencing coronary artery disease, heart failure, ischemic stroke, intracranial hemorrhage, composite cardiovascular outcomes, and all-cause mortality.
enm-2024-2176f3.jpg
enm-2024-2176f4.jpg
Table 1.
Comparison of Baseline Characteristics between Patients with Panhypopituitarism and Matched Controls
Variable Patients with panhypopituitarism (n=5,714) Controls (n=57,140) P value
Male sex 2,945 (51.5) 29,450 (51.5) 1.000
Age, yr 55.1±15.1 55.1±15.1 0.973
Median follow-up, mo 93.6 (46.6–149.2) 105.0 (52.8–161.2) <0.001
Income <0.001
 High 2,138 (38.0) 22,926 (40.6)
 Medium 1,954 (34.7) 20,265 (35.9)
 Low 1,540 (27.3) 13,257 (23.5)
Comorbidities
 Hypertension 2,084 (36.5) 17,975 (31.3) <0.001
 Dyslipidemia 3,222 (56.4) 23,536 (41.2) <0.001
 Diabetes mellitus 1,013 (17.7) 6,093 (10.7) <0.001
 Atrial fibrillation 127 (2.2) 1,427 (2.5) 0.218
 CAD 175 (3.1) 1,059 (1.9) <0.001
 Heart failure 344 (6.0) 2,751 (4.8) <0.001
 Ischemic stroke 613 (10.7) 2,242 (3.9) <0.001
 Hemorrhagic stroke 120 (2.1) 262 (0.5) <0.001
 Cancer 1,091 (19.1) 5,756 (10.1) <0.001
Treatment
 Brain surgery 2,725 (47.7) -
 Radiation therapy 185 (3.2) -
 Radiosurgery 567 (9.9) -
Hormone replacement
 GH user 110 (1.9) -
 Sex hormone user 470 (8.2) -
 Desmopressin user 1,810 (31.7) -

Values are expressed as number (%), mean±standard deviation, or median (interquartile range).

CAD, coronary artery disease; GH, growth hormone.

Table 2.
The Hazard Ratios for Cardiovascular Disease and Mortality in Patients with Panhypopituitarism Compared to Matched Controls: Male
Variable No. of events/No. of patients
 Duration, person-yr
 Events, /1,000 person-yr
 Model 1
 Model 2
Patients Controls Patients Controls Patients Controls HR (95% CI) P value HR (95% CI) P value
Coronary artery disease 35/2,278 368/22,780 18,183.40 197,606.50 1.9 1.9 1.08 (0.75–1.56) 0.665 1.07 (0.75–1.54) 0.706
Heart failure 150/2,253 1,268/22,530 17,697.75 192,653.36 8.5 6.6 1.29 (1.08–1.55) 0.005 1.30 (1.09–1.55) 0.004
Ischemic stroke 204/2,196 705/21,960 16,716.26 188,208.36 12.2 3.8 3.34 (2.83–3.95) <0.001 3.36 (2.86–3.96) <0.001
Intracranial hemorrhage 27/2,260 85/22,600 18,026.63 196,016.93 1.5 0.4 3.28 (2.10–5.12) <0.001 3.28 (2.10–5.11) <0.001
Composite cardiovascular outcomea 329/2,175 2,024/21,750 16,016.86 180,666.95 20.5 11.2 1.86 (1.64–2.11) <0.001 1.87 (1.66–2.12) <0.001
All-cause mortality 402/2,218 2,091/22,180 17,864.34 191,393.17 22.5 10.9 2.17 (1.95–2.42) <0.001 2.18 (1.95–2.43) <0.001

Model 1: adjustments were made for age, and index year; Model 2: adjustments were made for age, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, income.

Inverse probability of treatment weighting variables: age, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, and income.

HR, hazard ratio; CI, confidence interval.

a Composite cardiovascular outcome: combination of coronary artery disease, heart failure, ischemic stroke, and intracranial hemorrhage.

Table 3.
The Hazard Ratios for Cardiovascular Disease and Mortality in Patients with Panhypopituitarism Compared to Matched Controls: Female
Variable No. of events/No. of patients
 Duration, person-yr
 Events, /1,000 person-yr
 Model 1
 Model 2
Patients Controls Patients Controls Patients Controls HR (95% CI) P value HR (95% CI) P value
Coronary artery disease 35/2,214 210/22,140 20,716.82 225,874.85 1.7 0.9 1.76 (1.20–2.57) 0.004 1.79 (1.23–2.61) 0.002
Heart failure 226/2,180 1,740/21,800 19,725.90 216,006.30 11.6 8.1 1.44 (1.24–1.67) <0.001 1.46 (1.26–1.70) <0.001
Ischemic stroke 142/2,180 1,011/21,800 20,047.24 217,209.18 7.1 4.7 1.47 (1.22–1.77) <0.001 1.51 (1.25–1.81) <0.001
Intracranial hemorrhage 23/2,197 110/21,970 20,795.83 224,896.95 1.1 0.5 2.20 (1.38–3.52) 0.001 2.33 (1.45–3.73) 0.001
Composite cardiovascular outcomea 362/2,138 2,566/21,380 18,560.16 204,738.89 12.5 19.5 1.54 (1.37–1.73) <0.001 1.58 (1.41–1.78) <0.001
All-cause mortality 463/2,325 1,927/23,250 21,817.14 238,504.69 21.2 8.1 3.05 (2.75–3.39) <0.001 3.09 (2.78–3.44) <0.001

Model 1: adjustments were made for age, sex, and index year; Model 2: adjustments were made for age, sex, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, income. Inverse probability of treatment weighting variables: age, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, and income.

HR, hazard ratio; CI, confidence interval.

a Composite cardiovascular outcome: combination of coronary artery disease, heart failure, ischemic stroke, and intracranial hemorrhage.

Table 4.
Risk Factors to Composite Cardiovascular Outcomesa in Male with Panhypopituitarism
Variable Univariate (n=2,464)
 Multivariate (n=2,464)
OR (95% CI) P value OR (95% CI) P value
Age 1.04 (1.03–1.05) <0.001 1.03 (1.02–1.04) <0.001
Diabetes mellitus 2.00 (1.53–2.61) <0.001 1.48 (1.12–1.95) 0.005
Hypertension 2.19 (1.75–2.74) <0.001 1.42 (1.11–1.81) 0.005
Dyslipidemia 1.04 (0.83–1.29) 0.742 - -
Brain surgery 0.90 (0.73–1.12) 0.353 - -
Radiation therapy 1.00 (0.59–1.71) 0.993 - -
Radiosurgery 0.91 (0.63–1.33) 0.628 - -
Growth hormone replacement 0.49 (0.18–1.32) 0.160 - -
Desmopressin 0.90 (0.72–1.13) 0.380 - -
Craniopharyngioma 0.75 (0.55–1.01) 0.058 0.98 (0.72–1.34) 0.913

OR, odds ratio; CI, confidence interval.

a Composite cardiovascular outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

Table 5.
Risk Factors to Composite Cardiovascular Outcomesa in Female with Panhypopituitarism
Variable Univariate (n=2,287)
 Multivariate (n=2,287)
OR (95% CI) P value OR (95% CI) P value
Age 1.05 (1.04–1.05) <0.001 1.04 (1.03–1.05) <0.001
Diabetes mellitus 1.91 (1.47–2.47) <0.001 1.35 (1.02–1.77) 0.033
Hypertension 2.46 (1.99–3.03) <0.001 1.59 (1.25–2.01) <0.001
Dyslipidemia 1.65 (1.34–2.04) <0.001 1.16 (0.93–1.45) 0.196
Brain surgery 0.84 (0.66–1.06) 0.143 - -
Radiation therapy 1.23 (0.58–2.59) 0.593 - -
Radiosurgery 0.82 (0.49–1.38) 0.457 - -
Growth hormone 0.23 (0.07–0.71) 0.011 0.29 (0.09–0.92) 0.035
Sex hormone 0.43 (0.31–0.59) <0.001 0.74 (0.53–1.03) 0.074
Desmopressin 0.74 (0.55–0.98) 0.037 1.01 (0.75–1.36) 0.950
Craniopharyngioma 0.88 (0.62–1.25) 0.471 - -

OR, odds ratio; CI, confidence interval.

a Composite cardiovascular outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

Table 6.
Risk Factors to All-Cause Mortality in Male with Panhypopituitarism
Variable Univariate (n=2,464)
 Multivariate (n=2,464)
OR (95% CI) P value OR (95% CI) P value
Age 1.06 (1.05–1.07) <0.001 1.06 (1.05–1.07) <0.001
Diabetes mellitus 1.62 (1.28–2.05) <0.001 1.10 (0.86–1.41) 0.460
Hypertension 1.80 (1.48–2.19) <0.001 1.05 (0.84–1.32) 0.645
Dyslipidemia 1.03 (0.84–1.25) 0.780 - -
AF 0.96 (0.48–1.93) 0.906 - -
CAD 1.26 (0.74–2.15) 0.392 - -
HF 1.72 (1.12–2.64) 0.014 1.10 (0.71–1.70) 0.673
IS 1.89 (1.45–2.45) <0.001 1.17 (0.89–1.54) 0.273
ICH 1.23 (0.72–2.09) 0.454 - -
Brain surgery 0.65 (0.53–0.79) <0.001 0.70 (0.57–0.85) <0.001
Radiation therapy 2.40 (1.49–3.85) <0.001 3.77 (2.32–6.12) <0.001
Radiosurgery 1.06 (0.76–1.47) 0.742 - -
Growth hormone replacement 0.68 (0.32–1.44) 0.314 - -
Desmopressin 1.00 (0.81–1.23) 0.985 - -
Craniopharyngioma 0.81 (0.62–1.06) 0.125 - -

Composite outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; CAD, coronary artery disease; HF, heart failure; IS, ischemic stroke; ICH, intracranial hemorrhage.

Table 7.
Risk Factors to All-Cause Mortality in Female with Panhypopituitarism
Variable Univariate (n=2,478)
 Multivariate (n=2,478)
OR (95% CI) P value OR (95% CI) P value
Age 1.09 (1.08–1.01) <0.001 1.06 (1.05–1.07) <0.001
Diabetes mellitus 1.83 (1.47–2.26) <0.001 1.06 (0.83–1.36) 0.633
Hypertension 2.47 (2.06–2.97) <0.001 1.05 (0.84–1.32) 0.650
Dyslipidemia 1.12 (0.93–1.35) 0.229 - -
AF 3.24 (2.02–5.20) <0.001 0.72 (0.35–1.48) 0.379
CAD 2.10 (1.33–3.32) 0.002 0.80 (0.46–1.38) 0.414
HF 2.34 (1.74–3.16) <0.001 1.20 (0.77–1.88) 0.422
IS 2.66 (2.02–3.49) <0.001 1.18 (0.90–1.57) 0.236
ICH 1.99 (0.99–4.01) 0.053 1.02 (0.59–1.76) 0.936
Brain surgery 0.89 (0.71–1.10) 0.276 - -
Radiation therapy 2.18 (1.23–3.87) 0.008 3.54 (2.18–5.75) 0.005
Radiosurgery 1.30 (0.86–1.96) 0.214 - -
Growth hormone replacement 0.67 (0.36–1.25) 0.206 - -
Sex hormone replacement 0.38 (0.28–0.52) <0.001 0.87 (0.63–1.21) 0.417
Desmopressin 0.76 (0.58–0.99) 0.043 1.52 (1.23–1.89) <0.001
Craniopharyngioma 0.95 (0.68–1.32) 0.760 - -

Composite outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; CAD, coronary artery disease; HF, heart failure; IS, ischemic stroke; ICH, intracranial hemorrhage.

  • 1. Regal M, Paramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001;55:735–40.ArticlePubMedPDF
  • 2. Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet 2016;388:2403–15.ArticlePubMed
  • 3. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, et al. Mortality in patients with pituitary disease. Endocr Rev 2010;31:301–42.ArticlePubMedPDF
  • 4. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism: West Midlands prospective hypopituitary study group. Lancet 2001;357:425–31.PubMed
  • 5. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285–8.ArticlePubMed
  • 6. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75–81.PubMed
  • 7. Caicedo D, Diaz O, Devesa P, Devesa J. Growth hormone (GH) and cardiovascular system. Int J Mol Sci 2018;19:290.ArticlePubMedPMC
  • 8. Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med 2019;380:2551–62.ArticlePubMed
  • 9. Xing D, Nozell S, Chen YF, Hage F, Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009;29:289–95.ArticlePubMedPMC
  • 10. Stanhewicz AE, Wenner MM, Stachenfeld NS. Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan. Am J Physiol Heart Circ Physiol 2018;315:H1569–88.ArticlePubMedPMC
  • 11. Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol 2014;220:R37–55.ArticlePubMed
  • 12. Teixeira PF, Dos Santos PB, Pazos-Moura CC. The role of thyroid hormone in metabolism and metabolic syndrome. Ther Adv Endocrinol Metab 2020;11:2042018820917869.ArticlePubMedPMCPDF
  • 13. Khang AR, Ku EJ, Kim YA, Roh E, Bae JH, Oh TJ, et al. Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group. Pituitary 2016;19:573–81.ArticlePubMedPDF
  • 14. Bates AS, Van’t Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169–72.ArticlePubMed
  • 15. Bates AS, Bullivant B, Sheppard MC, Stewart PM. Life expectancy following surgery for pituitary tumours. Clin Endocrinol (Oxf) 1999;50:315–9.ArticlePubMedPDF
  • 16. Erfurth EM, Hagmar L. Cerebrovascular disease in patients with pituitary tumors. Trends Endocrinol Metab 2005;16:334–42.ArticlePubMed
  • 17. Cho SW, Kim JH, Choi HS, Ahn HY, Kim MK, Rhee EJ. Big data research in the field of endocrine diseases using the Korean National Health Information Database. Endocrinol Metab (Seoul) 2023;38:10–24.ArticlePubMedPMCPDF
  • 18. Erfurth EM, Bulow B, Nordstrom CH, Mikoczy Z, Hagmar L, Stromberg U. Doubled mortality rate in irradiated patients reoperated for regrowth of a macroadenoma of the pituitary gland. Eur J Endocrinol 2004;150:497–502.ArticlePubMed
  • 19. Garmes HM. Special features on insulin resistance, metabolic syndrome and vascular complications in hypopituitary patients. Rev Endocr Metab Disord 2024;25:489–504.ArticlePubMedPDF
  • 20. Samson SL, Ioachimescu AG. Pituitary disorders throughout the life cycle: a case-based guide. Cham: Springer International Publishing; 2022. Chapter 20, Minimising cardiometabolic risk factors in patients with hypopituitarism; p.245-60.
  • 21. Kaji H, Chihara K. Direct causes of death in Japanese patients with hypopituitarism as analyzed from a nation-wide autopsy database. Eur J Endocrinol 2004;150:149–52.ArticlePubMed
  • 22. Ebrahimi F, Kutz A, Wagner U, Illigens B, Siepmann T, Schuetz P, et al. Excess mortality among hospitalized patients with hypopituitarism: a population-based, matchedcohort study. J Clin Endocrinol Metab 2020;105:dgaa517.ArticlePubMedPDF
  • 23. Ngaosuwan K, Johnston DG, Godsland IF, Cox J, Majeed A, Quint JK, et al. Cardiovascular disease in patients with primary and secondary adrenal insufficiency and the role of comorbidities. J Clin Endocrinol Metab 2021;106:1284–93.ArticlePubMedPDF
  • 24. Olsson DS, Bryngelsson IL, Ragnarsson O. Higher incidence of morbidity in women than men with non-functioning pituitary adenoma: a Swedish nationwide study. Eur J Endocrinol 2016;175:55–61.ArticlePubMed
  • 25. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265–79.ArticlePubMed
  • 26. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.ArticlePubMed
  • 27. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023;389:107–17.PubMed
  • 28. Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004;89:3306–12.ArticlePubMed
  • 29. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000;85:1420–5.ArticlePubMed
  • 30. Jasim S, Alahdab F, Ahmed AT, Tamhane S, Prokop LJ, Nippoldt TB, et al. Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine 2017;56:33–42.ArticlePubMedPDF
  • 31. Stochholm K, Gravholt CH, Laursen T, Laurberg P, Andersen M, Kristensen LO, et al. Mortality and GH deficiency: a nationwide study. Eur J Endocrinol 2007;157:9–18.ArticlePubMed
  • 32. Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;2015:CD002229.ArticlePubMedPMC
  • 33. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD, Roger VL, Melton LJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16:15–23.ArticlePubMedPMC
  • 34. Elhadd TA, Abdu TA, Clayton RN. Excess vascular mortality in hypopituitarism: is it the result of estrogen or GH deficiency? J Clin Endocrinol Metab 2002;87:3509–10.ArticlePubMed
  • 35. Nielsen EH, Lindholm J, Laurberg P. Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf) 2007;67:693–7.ArticlePubMed
  • 36. Nielsen EH, Lindholm J, Laurberg P, Bjerre P, Christiansen JS, Hagen C, et al. Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 2007;10:67–73.ArticlePubMedPDF
  • 37. Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson BA, Cara J, Feldt-Rasmussen U, et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012;166:1069–77.ArticlePubMed
  • 38. van Bunderen CC, van Nieuwpoort IC, Arwert LI, Heymans MW, Franken AA, Koppeschaar HP, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency?: data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011;96:3151–9.ArticlePubMedPDF
  • 39. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999;84:453–7.ArticlePubMed
  • 40. Devin JK, Blevins LS, Verity DK, Chen Q, Bloodworth JR, Covington J, et al. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab 2007;92:3633–9.ArticlePubMedPDF
  • 41. Lee YJ, Choi Y, Yoo HW, Lee YA, Shin CH, Choi HS, et al. Metabolic impacts of discontinuation and resumption of recombinant human growth hormone treatment during the transition period in patients with childhood-onset growth hormone deficiency. Endocrinol Metab (Seoul) 2022;37:359–68.ArticlePubMedPMCPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      Cite
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study
      Endocrinol Metab. 2025;40(3):469-483.   Published online February 11, 2025
      DOI: https://doi.org/10.3803/EnM.2024.2176
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    • 2
    • 3
    Related articles
    Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study
    Image Image Image Image
    Fig. 1. Flow diagram of study subjects. E23- and E22- denote E23 and E22 and their subordinate codes, respectively.
    Fig. 2. Cumulative incidence curves for (A) coronary artery disease, (B) heart failure, (C) ischemic stroke, (D) intracranial hemorrhage, (E) composite cardiovascular outcome, and (F) all-cause mortality in male patients with panhypopituitarism. Cumulative incidence curves represent the proportion of individuals in each group (patients with panhypopituitarism and matched controls) experiencing coronary artery disease, heart failure, ischemic stroke, intracranial hemorrhage, composite cardiovascular outcomes, and all-cause mortality.
    Fig. 3. Cumulative incidence curves for (A) coronary artery disease, (B) heart failure, (C) ischemic stroke, (D) intracranial hemorrhage, (E) composite cardiovascular outcome, and (F) all-cause mortality in female patients with panhypopituitarism. Cumulative incidence curves represent the proportion of individuals in each group (patients with panhypopituitarism and matched controls) experiencing coronary artery disease, heart failure, ischemic stroke, intracranial hemorrhage, composite cardiovascular outcomes, and all-cause mortality.
    Graphical abstract

    Fig. 1.

    Fig. 2.

    Fig. 3.

    Graphical abstract

    Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study
    Variable Patients with panhypopituitarism (n=5,714) Controls (n=57,140) P value
    Male sex 2,945 (51.5) 29,450 (51.5) 1.000
    Age, yr 55.1±15.1 55.1±15.1 0.973
    Median follow-up, mo 93.6 (46.6–149.2) 105.0 (52.8–161.2) <0.001
    Income <0.001
     High 2,138 (38.0) 22,926 (40.6)
     Medium 1,954 (34.7) 20,265 (35.9)
     Low 1,540 (27.3) 13,257 (23.5)
    Comorbidities
     Hypertension 2,084 (36.5) 17,975 (31.3) <0.001
     Dyslipidemia 3,222 (56.4) 23,536 (41.2) <0.001
     Diabetes mellitus 1,013 (17.7) 6,093 (10.7) <0.001
     Atrial fibrillation 127 (2.2) 1,427 (2.5) 0.218
     CAD 175 (3.1) 1,059 (1.9) <0.001
     Heart failure 344 (6.0) 2,751 (4.8) <0.001
     Ischemic stroke 613 (10.7) 2,242 (3.9) <0.001
     Hemorrhagic stroke 120 (2.1) 262 (0.5) <0.001
     Cancer 1,091 (19.1) 5,756 (10.1) <0.001
    Treatment
     Brain surgery 2,725 (47.7) -
     Radiation therapy 185 (3.2) -
     Radiosurgery 567 (9.9) -
    Hormone replacement
     GH user 110 (1.9) -
     Sex hormone user 470 (8.2) -
     Desmopressin user 1,810 (31.7) -
    Variable No. of events/No. of patients
    		 Duration, person-yr
    		 Events, /1,000 person-yr
    		 Model 1
    		 Model 2
    Patients Controls Patients Controls Patients Controls HR (95% CI) P value HR (95% CI) P value
    Coronary artery disease 35/2,278 368/22,780 18,183.40 197,606.50 1.9 1.9 1.08 (0.75–1.56) 0.665 1.07 (0.75–1.54) 0.706
    Heart failure 150/2,253 1,268/22,530 17,697.75 192,653.36 8.5 6.6 1.29 (1.08–1.55) 0.005 1.30 (1.09–1.55) 0.004
    Ischemic stroke 204/2,196 705/21,960 16,716.26 188,208.36 12.2 3.8 3.34 (2.83–3.95) <0.001 3.36 (2.86–3.96) <0.001
    Intracranial hemorrhage 27/2,260 85/22,600 18,026.63 196,016.93 1.5 0.4 3.28 (2.10–5.12) <0.001 3.28 (2.10–5.11) <0.001
    Composite cardiovascular outcomea 329/2,175 2,024/21,750 16,016.86 180,666.95 20.5 11.2 1.86 (1.64–2.11) <0.001 1.87 (1.66–2.12) <0.001
    All-cause mortality 402/2,218 2,091/22,180 17,864.34 191,393.17 22.5 10.9 2.17 (1.95–2.42) <0.001 2.18 (1.95–2.43) <0.001
    Variable No. of events/No. of patients
    		 Duration, person-yr
    		 Events, /1,000 person-yr
    		 Model 1
    		 Model 2
    Patients Controls Patients Controls Patients Controls HR (95% CI) P value HR (95% CI) P value
    Coronary artery disease 35/2,214 210/22,140 20,716.82 225,874.85 1.7 0.9 1.76 (1.20–2.57) 0.004 1.79 (1.23–2.61) 0.002
    Heart failure 226/2,180 1,740/21,800 19,725.90 216,006.30 11.6 8.1 1.44 (1.24–1.67) <0.001 1.46 (1.26–1.70) <0.001
    Ischemic stroke 142/2,180 1,011/21,800 20,047.24 217,209.18 7.1 4.7 1.47 (1.22–1.77) <0.001 1.51 (1.25–1.81) <0.001
    Intracranial hemorrhage 23/2,197 110/21,970 20,795.83 224,896.95 1.1 0.5 2.20 (1.38–3.52) 0.001 2.33 (1.45–3.73) 0.001
    Composite cardiovascular outcomea 362/2,138 2,566/21,380 18,560.16 204,738.89 12.5 19.5 1.54 (1.37–1.73) <0.001 1.58 (1.41–1.78) <0.001
    All-cause mortality 463/2,325 1,927/23,250 21,817.14 238,504.69 21.2 8.1 3.05 (2.75–3.39) <0.001 3.09 (2.78–3.44) <0.001
    Variable Univariate (n=2,464)
    		 Multivariate (n=2,464)
    OR (95% CI) P value OR (95% CI) P value
    Age 1.04 (1.03–1.05) <0.001 1.03 (1.02–1.04) <0.001
    Diabetes mellitus 2.00 (1.53–2.61) <0.001 1.48 (1.12–1.95) 0.005
    Hypertension 2.19 (1.75–2.74) <0.001 1.42 (1.11–1.81) 0.005
    Dyslipidemia 1.04 (0.83–1.29) 0.742 - -
    Brain surgery 0.90 (0.73–1.12) 0.353 - -
    Radiation therapy 1.00 (0.59–1.71) 0.993 - -
    Radiosurgery 0.91 (0.63–1.33) 0.628 - -
    Growth hormone replacement 0.49 (0.18–1.32) 0.160 - -
    Desmopressin 0.90 (0.72–1.13) 0.380 - -
    Craniopharyngioma 0.75 (0.55–1.01) 0.058 0.98 (0.72–1.34) 0.913
    Variable Univariate (n=2,287)
    		 Multivariate (n=2,287)
    OR (95% CI) P value OR (95% CI) P value
    Age 1.05 (1.04–1.05) <0.001 1.04 (1.03–1.05) <0.001
    Diabetes mellitus 1.91 (1.47–2.47) <0.001 1.35 (1.02–1.77) 0.033
    Hypertension 2.46 (1.99–3.03) <0.001 1.59 (1.25–2.01) <0.001
    Dyslipidemia 1.65 (1.34–2.04) <0.001 1.16 (0.93–1.45) 0.196
    Brain surgery 0.84 (0.66–1.06) 0.143 - -
    Radiation therapy 1.23 (0.58–2.59) 0.593 - -
    Radiosurgery 0.82 (0.49–1.38) 0.457 - -
    Growth hormone 0.23 (0.07–0.71) 0.011 0.29 (0.09–0.92) 0.035
    Sex hormone 0.43 (0.31–0.59) <0.001 0.74 (0.53–1.03) 0.074
    Desmopressin 0.74 (0.55–0.98) 0.037 1.01 (0.75–1.36) 0.950
    Craniopharyngioma 0.88 (0.62–1.25) 0.471 - -
    Variable Univariate (n=2,464)
    		 Multivariate (n=2,464)
    OR (95% CI) P value OR (95% CI) P value
    Age 1.06 (1.05–1.07) <0.001 1.06 (1.05–1.07) <0.001
    Diabetes mellitus 1.62 (1.28–2.05) <0.001 1.10 (0.86–1.41) 0.460
    Hypertension 1.80 (1.48–2.19) <0.001 1.05 (0.84–1.32) 0.645
    Dyslipidemia 1.03 (0.84–1.25) 0.780 - -
    AF 0.96 (0.48–1.93) 0.906 - -
    CAD 1.26 (0.74–2.15) 0.392 - -
    HF 1.72 (1.12–2.64) 0.014 1.10 (0.71–1.70) 0.673
    IS 1.89 (1.45–2.45) <0.001 1.17 (0.89–1.54) 0.273
    ICH 1.23 (0.72–2.09) 0.454 - -
    Brain surgery 0.65 (0.53–0.79) <0.001 0.70 (0.57–0.85) <0.001
    Radiation therapy 2.40 (1.49–3.85) <0.001 3.77 (2.32–6.12) <0.001
    Radiosurgery 1.06 (0.76–1.47) 0.742 - -
    Growth hormone replacement 0.68 (0.32–1.44) 0.314 - -
    Desmopressin 1.00 (0.81–1.23) 0.985 - -
    Craniopharyngioma 0.81 (0.62–1.06) 0.125 - -
    Variable Univariate (n=2,478)
    		 Multivariate (n=2,478)
    OR (95% CI) P value OR (95% CI) P value
    Age 1.09 (1.08–1.01) <0.001 1.06 (1.05–1.07) <0.001
    Diabetes mellitus 1.83 (1.47–2.26) <0.001 1.06 (0.83–1.36) 0.633
    Hypertension 2.47 (2.06–2.97) <0.001 1.05 (0.84–1.32) 0.650
    Dyslipidemia 1.12 (0.93–1.35) 0.229 - -
    AF 3.24 (2.02–5.20) <0.001 0.72 (0.35–1.48) 0.379
    CAD 2.10 (1.33–3.32) 0.002 0.80 (0.46–1.38) 0.414
    HF 2.34 (1.74–3.16) <0.001 1.20 (0.77–1.88) 0.422
    IS 2.66 (2.02–3.49) <0.001 1.18 (0.90–1.57) 0.236
    ICH 1.99 (0.99–4.01) 0.053 1.02 (0.59–1.76) 0.936
    Brain surgery 0.89 (0.71–1.10) 0.276 - -
    Radiation therapy 2.18 (1.23–3.87) 0.008 3.54 (2.18–5.75) 0.005
    Radiosurgery 1.30 (0.86–1.96) 0.214 - -
    Growth hormone replacement 0.67 (0.36–1.25) 0.206 - -
    Sex hormone replacement 0.38 (0.28–0.52) <0.001 0.87 (0.63–1.21) 0.417
    Desmopressin 0.76 (0.58–0.99) 0.043 1.52 (1.23–1.89) <0.001
    Craniopharyngioma 0.95 (0.68–1.32) 0.760 - -
    Table 1. Comparison of Baseline Characteristics between Patients with Panhypopituitarism and Matched Controls

    Values are expressed as number (%), mean±standard deviation, or median (interquartile range).

    CAD, coronary artery disease; GH, growth hormone.

    Table 2. The Hazard Ratios for Cardiovascular Disease and Mortality in Patients with Panhypopituitarism Compared to Matched Controls: Male

    Model 1: adjustments were made for age, and index year; Model 2: adjustments were made for age, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, income.

    Inverse probability of treatment weighting variables: age, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, and income.

    HR, hazard ratio; CI, confidence interval.

    Composite cardiovascular outcome: combination of coronary artery disease, heart failure, ischemic stroke, and intracranial hemorrhage.

    Table 3. The Hazard Ratios for Cardiovascular Disease and Mortality in Patients with Panhypopituitarism Compared to Matched Controls: Female

    Model 1: adjustments were made for age, sex, and index year; Model 2: adjustments were made for age, sex, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, income. Inverse probability of treatment weighting variables: age, index year, baseline hypertension, baseline dyslipidemia, baseline diabetes mellitus, and income.

    HR, hazard ratio; CI, confidence interval.

    Composite cardiovascular outcome: combination of coronary artery disease, heart failure, ischemic stroke, and intracranial hemorrhage.

    Table 4. Risk Factors to Composite Cardiovascular Outcomesa in Male with Panhypopituitarism

    OR, odds ratio; CI, confidence interval.

    Composite cardiovascular outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

    Table 5. Risk Factors to Composite Cardiovascular Outcomesa in Female with Panhypopituitarism

    OR, odds ratio; CI, confidence interval.

    Composite cardiovascular outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

    Table 6. Risk Factors to All-Cause Mortality in Male with Panhypopituitarism

    Composite outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

    OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; CAD, coronary artery disease; HF, heart failure; IS, ischemic stroke; ICH, intracranial hemorrhage.

    Table 7. Risk Factors to All-Cause Mortality in Female with Panhypopituitarism

    Composite outcome: coronary artery disease or ischemic stroke or intracranial hemorrhage or heart failure.

    OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; CAD, coronary artery disease; HF, heart failure; IS, ischemic stroke; ICH, intracranial hemorrhage.

    Table 1.

    Table 2.

    Table 3.

    Table 4.

    Table 5.

    Table 6.

    Table 7.

    Endocrinol Metab : Endocrinology and Metabolism
    © Korean Endocrine Society.
    TOP